Put companies on watchlist
MediClin AG
ISIN: DE0006595101
WKN: 659510
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

MediClin AG · ISIN: DE0006595101 · EQS - Company News (52 News)
Country: Germany · Primary market: Germany · EQS NID: 1731845
21 September 2023 04:00PM

Thomas Piefke becomes a member of MEDICLIN's Management Board and will be responsible for the post-acute segment in the future


EQS-News: MediClin AG / Key word(s): Personnel
MediClin AG: Thomas Piefke becomes a member of MEDICLIN's Management Board and will be responsible for the post-acute segment in the future

21.09.2023 / 16:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Offenburg, 21 September 2023

Thomas Piefke becomes a member of MEDICLIN's Management Board and will be responsible for the post-acute segment in the future

In its meeting today, the Supervisory Board of MEDICLIN Aktiengesellschaft (MEDICLIN) appointed Thomas Piefke as a member of MEDICLIN's Management Board. Effective October 1, 2023, Thomas Piefke will succeed Dr. York Dhein, who will resign from his position as a member of the company's Management Board by mutual agreement with the Supervisory Board on September 30, 2023, to pursue new professional challenges.

"Dr. Dhein has led our company operationally out of the Corona crisis and launched fields of activity such as teletherapy as well as new and innovative outpatient offerings. We thank him for his commitment and the work he has done and wish him all the best for his professional and private future. At the same time, we are pleased to have gained an expert with many years of industry experience in Thomas Piefke," said Dr. Jan Liersch, Chairman of the Supervisory Board of MEDICLIN.

Thomas Piefke has been active in leading positions in the healthcare sector for about 27 years. A graduate in health economics, he worked for many years as a regional manager for rehabilitation and managing director of a major German clinic providers across Germany before joining the Asklepios Group as managing director in 2017. He currently heads the Asklepios Nordseeklinik Westerland/Sylt, a large rehabilitation clinic and an acute clinic work closely together under one roof.

"I am very much looking forward to bring in my experience to MEDICLIN in the future," said Thomas Piefke and added: "Medical care at a high level and a good interaction between acute hospital and rehabilitation clinic are essential success factors for me. This interaction, and thus especially the special offer of rehabilitation, require new innovative approaches, because only in this way the entire recovery process of our patients can be improved."

In its clinics, MEDICLIN offers qualified medical services in acute medicine (acute segment), rehabilitation (post-acute segment) and, at some locations, inpatient care services. This setup enables MEDICLIN to pursue a business model that allows for interdisciplinary care of patients. In addition, outpatient and inpatient acute medical and rehabilitative services are networked, which increases efficiency in healthcare provision while ensuring a high standard of quality along the entire treatment chain.

 

About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)

MEDICLIN includes 32 clinics, six care facilities and ten medical care centers. The Group has around 8,300 beds/care places and employs around 10,000 people. In a strong network, MEDICLIN offers the patient integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.

 

MEDICLIN ─ a company of the Asklepios Group



21.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: MediClin AG
Okenstraße 27
77652 Offenburg
Germany
Phone: +49 (0)781 488-326
Fax: +49 (0)781 488-184
E-mail: alexandra.muehr@mediclin.de
Internet: www.mediclin.de
ISIN: DE0006595101
WKN: 659510
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1731845

 
End of News EQS News Service

1731845  21.09.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1731845&application_name=news&site_id=boersengefluester
Visual performance / price development - MediClin AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.